No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of ...

With positive results for patients with the chronic skin condition, Jasper Therapeutics’ briquilimab is looking to take on ...

CD117 (Kit) or C-Kit is a growth factor receptor on mast cells. When a molecule called stem cell factor attaches to C-Kit, the development of mast cells results. A mutation of the receptor causes ...

Briquilimab (formerly JSP191) is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor c-Kit, also known as CD117, thereby inhibiting ...

Lundbeck A/S is to acquire Longboard Pharmaceuticals Inc. in an all-cash deal valuing the epilepsy specialist at $2.6 billion. The agreed price of $60 per share is a 54% premium to the closing price ...

▎药明康德内容团队编辑今日，JasperTherapeutics公布其进行中SPOTLIGHT临床1b/2a期研究的初步数据。分析显示，慢性诱发性荨麻疹（CIndU）患者在接受其在研药物briquilimab皮下注射后1周便观察到完全缓解（CR），且 ...

作者|张小英，朱益，李诗琦指导老师：李玉芹、吴昊单位|成飞医院前言骨髓增生异常综合征（myelodysplasticsyndrome-s，MDS）是起源于造血干细胞的一组异质性髓系克隆性疾病,各年龄组均可发生，少数为儿童，特点是髓系细胞发育异常,表现 ...

Here, to our knowledge, we present the first known case of a patient with TAR syndrome who developed Philadelphia-chromosome positive (Ph+) AML, which accounts for only about 1% of newly diagnosed AML ...

No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6 th, 2025, including 180mg Q8W cohort Company to host conference call ...